Cargando…
Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
BACKGROUND: Agonists of 5‐hydroxytryptamine 4 receptor are potential agents for irritable bowel syndrome with predominant constipation (IBS‐C). However, only tegaserod has been approved for a very limited population in the US. AIM: To evaluate the efficacy and safety of minesapride in patients with...
Autores principales: | Hamatani, Tatsuto, Fukudo, Shin, Nakada, Yosuke, Inada, Hiroshi, Kazumori, Kiyoyasu, Miwa, Hiroto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383621/ https://www.ncbi.nlm.nih.gov/pubmed/32583907 http://dx.doi.org/10.1111/apt.15907 |
Ejemplares similares
-
Randomised clinical trial: exploratory phase 2 study of ONO‐2952 in diarrhoea‐predominant irritable bowel syndrome
por: Whitehead, W. E., et al.
Publicado: (2016) -
Randomised clinical trial: low‐FODMAP rye bread vs. regular rye bread to relieve the symptoms of irritable bowel syndrome
por: Laatikainen, R., et al.
Publicado: (2016) -
Randomised controlled trial: effects of gluten‐free diet on symptoms and the gut microenvironment in irritable bowel syndrome
por: Algera, Joost P., et al.
Publicado: (2022) -
Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation
por: Mourey, Florian, et al.
Publicado: (2022) -
Randomised clinical trial: linaclotide vs placebo—a study of bi‐directional gut and brain axis
por: Rao, Satish S.C., et al.
Publicado: (2020)